These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547 [TBL] [Abstract][Full Text] [Related]
7. Vaccines for lymphomas: idiotype vaccines and beyond. Houot R; Levy R Blood Rev; 2009 May; 23(3):137-42. PubMed ID: 18951668 [TBL] [Abstract][Full Text] [Related]
8. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression. Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777 [TBL] [Abstract][Full Text] [Related]
9. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma. Koç ON; Redfern C; Wiernik PH; Rosenfelt F; Winter JN; Carter WD; Gold DP; Stewart ME; Ghalie RG; Bender JF J Immunother; 2010; 33(2):178-84. PubMed ID: 20145546 [TBL] [Abstract][Full Text] [Related]
10. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. Inogès S; Rodrìguez-Calvillo M; Zabalegui N; Lòpez-Dìaz de Cerio A; Villanueva H; Soria E; Suárez L; Rodríguez-Caballero A; Pastor F; García-Muñóz R; Panizo C; Pèrez-Calvo J; Melero I; Rocha E; Orfao A; Bendandi M; ; J Natl Cancer Inst; 2006 Sep; 98(18):1292-301. PubMed ID: 16985248 [TBL] [Abstract][Full Text] [Related]
11. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Ruffini PA; Neelapu SS; Kwak LW; Biragyn A Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812 [TBL] [Abstract][Full Text] [Related]
12. Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure. Longo DL J Natl Cancer Inst; 2006 Sep; 98(18):1263-5. PubMed ID: 16985240 [No Abstract] [Full Text] [Related]
13. Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study. Yáñez R; Barrios Y; Ruiz E; Cabrera R; Díaz-Espada F J Immunother; 2008 Apr; 31(3):310-2. PubMed ID: 18317357 [TBL] [Abstract][Full Text] [Related]
16. Lymphoma vaccine therapy: next steps after a positive, controlled phase III clinical trial. Thomas SK; Kwak LW Semin Oncol; 2012 Jun; 39(3):253-62. PubMed ID: 22595048 [TBL] [Abstract][Full Text] [Related]
17. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma. Gadri Z; Kukulansky T; Bar-Or E; Haimovich J; Hollander N J Immunother; 2009 May; 32(4):333-40. PubMed ID: 19342972 [TBL] [Abstract][Full Text] [Related]
18. Vaccine strategies in the treatment of low-grade non-Hodgkin lymphoma. Koumarianou A; Kountourakis P; Economopoulos T J Steroid Biochem Mol Biol; 2008 Apr; 109(3-5):230-2. PubMed ID: 18406604 [TBL] [Abstract][Full Text] [Related]
19. Phase III randomized study of autologous lymphoma-derived idiotype specific vaccination plus GM-CSF in patients with follicular lymphoma in first complete remission. Clin Adv Hematol Oncol; 2003 Jan; 1(1):67. PubMed ID: 16227966 [No Abstract] [Full Text] [Related]
20. New agents in follicular lymphoma. Cheson BD Best Pract Res Clin Haematol; 2011 Jun; 24(2):305-12. PubMed ID: 21658626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]